Alzheimer's disease (AD) causes gradual cognitive decline and dementia.
Until recently, the definitive diagnosis of AD was based on autopsy assessments of brain amyloid-β plaques and tau neurofibrillary tangles, the defining biological features of AD. Biomarkers of amyloid-β and tau are vital for measuring AD pathology in living people and for differentiating between different neurodegenerative diseases.
With the latest progress in AD research, accurate in-vivo diagnosis of AD is becoming increasingly crucial: before starting treatment with anti-amyloid therapies, it's essential to determine if amyloid positivity is present. This article...
In what can potentially be a gamechanger in treating Alzheimer’s disease, scientists at the Technical University of Munich (TUM) has unveiled the root cause...
In this video Doctor O'Donovan explains how to use DONEPEZIL (aka Aricept) a medication used in the treatment of DEMENTIA (e.g. Alzheimer's disease, dementia...
Are you worried about memory loss or cognitive decline?
In this short and informative video, Dr. Raveesh Sunkara, a neurosurgeon, discusses the early signs...
🥦 Start your Blueprint protocol:
📩 Get my latest protocols:
Let’s be friends:
Twitter:
Instagram:
TikTok:
Project Blueprint and Don’t Die celebrate that we, humanity,...
Dr. Kapil Singhal (Director – Neurosciences, Medanta, Noida) highlights the early indicators of Alzheimer’s disease.
These may include:
- Forgetting everyday details or important dates
- Confusion...